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a b s t r a c t
Alternaria alternata is a fungal allergen linked to the development of severe asthma in humans. In view of
the clinical relationship between A. alternata and asthma, we sought to investigate the allergic activity of
this antigen after direct application to the lungs of Brown Norway rats.
Here we demonstrate that a single intratracheal instillation of A. alternata induces dose and time
dependent eosinophil inﬂux, edema and Type 2 helper cell cytokine production in the lungs of BN rats.
We established the temporal proﬁle of eosinophilic inﬁltration and cytokine production, such as
Interleukin-5 and Interleukin-13, following A. alternata challenge. These responses were comparable to
Ovalbumin induced models of asthma and resulted in peak inﬂammatory responses 48 h following a
single challenge, eliminating the need for multiple sensitizations and challenges. The initial perivascular
and peribronchiolar inﬂammation preceded alveolar inﬂammation, progressing to a more sub-acute
inﬂammatory response with notable epithelial cell hypertrophy. To limit the effects of an A. alternata
inﬂammatory response, MK-7246 was utilized as it is an antagonist for Chemoattractant Receptor-
homologous molecule expressed in Th2 cells. In a dose-dependent manner, MK-7246 decreased
eosinophil inﬂux and Th2 cytokine production following the A. alternata challenge. Furthermore,
therapeutic administration of corticosteroids resulted in a dose-dependent decrease in eosinophil inﬂux
and Th2 cytokine production.
Reproducible asthma-related outcomes and amenability to pharmacological intervention by mechan-
isms relevant to asthma demonstrate that an A. alternata induced pulmonary inﬂammation in BN rats is
a valuable preclinical pharmacodynamic in vivo model for evaluating the pharmacological inhibitors of
allergic pulmonary inﬂammation.
& 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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1. Introduction
Asthma is a heterogeneous respiratory disease with a complex
pathophysiology. It continues to be a signiﬁcant societal health burden,
utilizes a large amount of health resources, and diminishes quality of
life (Adcock et al., 2008; Bel, 2013). Particularly noteworthy are a small
percentage of patients with severe symptoms leading to signiﬁcant
airway obstruction, which require frequent hospital admissions due to
exacerbated asthma symptoms and are refractory to standard of care
drugs. While these refractory asthmatics represent only a small
percentage of asthmatic patients, the medical costs for treating
refractory asthmatics represents about 50% of the total healthcare cost
for asthma (Jang, 2012). The disease is characterized by a persistent
Th2 inﬂammation, airﬂow obstruction, bronchoconstriction and air-
way hyperresponsiveness (Howarth, 1995). While “asthma triggers”
are loosely deﬁned as substances or events that precipitate an acute
onset or worsening of asthma symptoms (Vernon et al., 2012), the
temporal understanding of the pathways by which these triggers drive
respiratory pathophysiology are not fully understood. Nonetheless, it is
well accepted that exposing asthmatics to aeroallergens, viruses, and
respiratory irritants leads to an aggravation of the disease (Kim and
Gern, 2012). In recent years, fungi sensitization has emerged as an
important potential contributor to allergic lower airway disease
(Knutsen et al., 2012). Indeed, patients with allergic asthma often
have detectable levels of serum IgE antibodies to fungi (Crameri et al.,
2009). Schwartz et al. (1978) was the ﬁrst to describe a relationship
between Aspergillus skin test reactivity and the severity of airway
obstruction in asthmatic patients. Subsequently, links between sensi-
tization of various fungi (e.g. Alternaria, Aspergillus, Aureobasidium,
Cladosporium, Helminthosporium and Trichophyton) to respiratory
pathology were suggested (Peat et al., 1993; Neukirch et al., 1999; Fairs
et al., 2010; Agarwal, 2011). For instance, Arbes et al. (2007) found that
A. alternata is independently associated with asthma cases attributable
to atopy. Further support for a relationship between A. alternata and
asthma includes the following observations: (1) Childhood sensitiza-
tion to A. alternata correlates with persistent adult asthma (Stern, et al.,
2008); (2) sensitization to A. alternata is associated with fatal episodes
of asthma (Arbes et al., 2007; Knutsen et al., 2010), (3) when delivered
directly to the airways, A. alternata spores induce brochoconstriction in
people with mild asthma (Licorish et al., 1985) and (4) environmental
ﬂuctuations in A. alternata spore counts appear to associate with
symptom severity, as observed in the cases of “thunderstorm asthma”,
where there is a signiﬁcant rise in this airborne antigen (Pulimood
et al., 2007; Nasser and Pulimood, 2009).
The mechanism(s) and pathways by which A. alternata initiates
respiratory inﬂammation in sensitized patients are not fully
understood. However, it is known that certain key immune cells
such as lung epithelial cells, dendritic cells, and eosinophils likely
play a pivotal role in orchestrating a Th2-mediated inﬂammation
precipitated by lung exposure to A. alternata antigens. Murai et al.
(2012) demonstrated that A. alternata extracts in cultured human
bronchial epithelial cells induce the rapid release of Interleukin-18
(IL-18) which can directly promote Th2 differentiation of naïve
CD4þ T-cells through a NF-κB dependent pathway (Murai et al.,
2012). Another route through which A. alternata and other fungi
may induce Th2 inﬂammation is by the activation of a protease-
activated receptor, particularly Protease Activated Receptor-2
(Matsuwaki et al., 2011). In view of the clinical relationship
between A. alternata and asthma, we sought to characterize the
activity of this antigen after direct application to the lungs of BN
rats. In this study, we describe a novel Th2-mediated model of
pulmonary inﬂammation due to the acute intratracheal instillation
of A. alternata in Brown Norway rats. In addition, we conducted
pharmacological validation of this model using clinically relevant
drugs, such as glucocorticoids and a CRTH2 antagonist, MK-7246
(Gervais et al., 2010).
2. Materials and methods
2.1. Animal care and use
All studies were performed in accordance with the National
Institute of Health Guide to the Care and Use of Laboratory Animals
and the Animal Welfare Act, in Association with the Assessment
and Laboratory Animal Care Program. All experiments were
approved by Merck Institutional Animal Care and Use Committee.
2.2. Characterization of A. alternata evoked pulmonary
inﬂammation responses in brown Norway rats
Male Brown Norway rats (225–275 g) were purchased from
Charles River Laboratories (Kingston, NY) and housed in an animal
room at a temperature of 25 1C (75 1C), relative humidity:
30–70%, a daily light–dark cycle (07:00 to 19:00 light). Chow and
water were supplied ad libitum and the animals were studied
between 80 and 85 days of age. Experimental rats were intra-
tracheally challenged with A. alternata extracts (Greer Labs, Lenoir,
NC) in 100 μl sterile phosphate buffered saline (PBS), using a Penn-
Century microsprayer device (Penn-Century, Philadelphia, PA).
A series of experiments were conducted to examine: (1) the
impact of A. alternata on respiratory inﬂammation, (i.e. total BAL
ﬂuid cells, eosinophils and neutrophils) after topical administra-
tion to the lungs (n¼8 animals per treatment group); (2) the
temporal relationship between Th2 cytokine secretion and inﬂam-
matory cellular inﬂux into the BAL ﬂuid after a single intratracheal
A. alternata challenge (n¼8 animals per treatment group); (3) his-
tological and CT scan observations after an A. alternata challenge
(n¼6 animals per treatment group); and (4) pharmacological
intervention of A. alternata responses by classical glucocorticoids
(i.e. budesonide) and by MK-7246, a selective orally active CRTH2
antagonist (n¼8 animals per treatment group).
2.3. Impact of A. alternata on respiratory inﬂammation and the
temporal relationship of Th2 cytokine secretions
To determine if rats that were given increasing doses (500–
2000 μg) of intratracheal A. alternata induced a more severe
inﬂammatory response, BAL ﬂuid cell composition was analyzed
at 24 and 48 h post-provocation. BAL ﬂuid collection and proces-
sing were carried out using the methods previously described
(Lieber et al., 2013). Brieﬂy, after an overdose (150–200 mg/kg via
intratperitoneal injection) of pentobarbital, the trachea was cathe-
terized, BAL ﬂuid was obtained by the intratracheal insertion of a
catheter, followed by two lavages with 3 ml 0.9% sodium chloride
injection, USP (Hospira, Lake Forest, IL). One aliquot (2 ml), was
analyzed for total and differential cell counts performed using an
Advia 120 Automated Hematology Analyzer (Siemens, Washington
DC). For some studies, a small BAL ﬂuid aliquot (0.5 ml) was
collected for cytokine analysis. Speciﬁcally, BAL ﬂuid samples were
centrifuged at 1500g, 4 1C for 10 min to eliminate cellular debris
and supernatant was aliquoted and frozen at 80 1C for further
analysis. Once defrosted, a Luminex-Milliplex MAP magnetic bead-
based Rat 22-plex immunoassay (Millipore, Billerica, MA) analysis
of BAL ﬂuid supernatants was performed following manufacturer's
directions. We also utilized a Meso Scale Discovery (MSD, Rock-
ville, MD) Rat 7plex ultra-sensitive kit for a panel of certain
cytokines. ELISA for IL-13 (Invitrogen, Grand Island, NY) was
performed on the BAL ﬂuid supernatant according to the manu-
facturer's instructions and all ELISA plates were read with a BioRad
Model 680 microplate reader.
In separate studies, the time related (i.e. 24, 48, 72 and 96 h)
effects of A. alternata on BAL ﬂuid cells and cytokines were deter-
mined. Additional characterization of the effects of locally applied
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A. alternata to the airways was studied, utilizing histological and
imaging methodologies (see below).
2.4. Pharmacological actions of glucocorticoids and MK-7246 on
pulmonary inﬂammation responses in Brown Norway rats
Intratracheal budesonide was dosed 1 h prior to and 23 h post the
A. alternata intratracheal dose while oral budesonide (3 mg kg1)
was administered 2 h before and 22 h post the A. alternata extract
instillation. An intratracheally dosed budesonide was prepared using
the Covaris formulation as described (Kakumanu and Schroeder,
2012). Covaris AFA is an in-situ method which allows the construc-
tion of tightly distributed suspensions, achieving micron sized
(1–10 μm) suspensions using Covaris Focused-ultrasonicator E220.
MK-7246 (3, 10, 30 and 100 mg kg1) was administered orally 1 h
before and 23 h post an A. alternata extract instillation in order to
examine the effect of the CRTH2 antagonist on A. alternata elicited
pulmonary inﬂammatory responses. Budesonide dosed orally was
used as a positive control in both experiments. The animals were
lightly anesthetized with 3% isoﬂurane (supplemented with 100%
oxygen), either 2 h following an oral dosing or 1 h following an
intratracheal dosing. The animals were also secured on a rodent work
stand to facilitate the localization of the larynx and tracheal openings.
The microsprayer needle was inserted into the trachea and 0.1 ml of
10,000 μg ml1 (total of 1000 μg) A. alternata extract was adminis-
tered using a microsprayer. The animals were observed until they
recovered from anesthesia and then returned to their cages and
allowed food and water ad libitum. The animals were euthanized
with an overdose of pentobarbital 48 h after an A. alternata intra-
tracheal instillation and BAL ﬂuid was collected.
2.5. Micro-CT imaging acquisition, image reconstruction, and
analysis
CT scans were performed on rats anesthetized with 3% isoﬂur-
ane (supplemented with 100% oxygen), using a GE eXplore Locus
Ultra Pre-Clinical CT scanner (GE Healthcare, Cleveland, OH, USA).
Rats were imaged one at a time. The entire chest area was scanned
at once, with 1000 projections collected in one full rotation of the
gantry in approximately 16 s. The X-ray tube settings were 80 kV
and 70 mA and the isotropic resolution was 185 μm.
Projection data was reconstructed using the graphics proces-
sing unit (GPU)-based AxRecon reconstruction platform (Accele-
ware, Inc., Ontario, Canada). The three dimensions of the image
data set (x, y, and z), were manually adjusted to 600500800
slices at 100 μm cubic voxel dimensions for reconstruction and
images were scaled to Hounsﬁeld units. The reconstructed data
was then cropped into the easier-to-manage Analyze format using
a MATLAB (MathWorks, Inc., Natick, MA) application that was
developed to automate this conversion process.
An image analysis method we used was based on a method
published by Haines et al. (2009) that relies on thresh-holding and
region-grow algorithms to segment separate anatomical regions of
interest using the Amira 5.4.2 software (Mercury Computer Systems,
Inc., Chelmsford, MA). We adjusted the functional lung volume from
1000 to 300 since the current studies utilized a rat instead of a
mouse model. After the functional volume was recorded, the total
chest space was selected using semi-automated contouring and
manual selection, eliminating the heart and liver. Vasculature found
in the lung was included in this total lung measurement, since
edema and vascular tissues have similar grayscale values and cannot
be differentiated based on threshold. Once the total chest space was
determined for each animal, the functional chest space was sub-
tracted from that volume, leaving the intentionally selected vascu-
lature, as well as edema. The ﬁnal readout, (Edema volume with
vasculature¼Total chest volume functional lung volume), was the
edema plus the vascular tissue, which should remain relatively
constant given the weeklong timeframe of this type of study.
2.6. Histopathological analysis
Lungs from 6 rats/group were obtained at the scheduled
terminations of 6, 24, 48, or 72 h following the challenge, along
with lungs from naïve animals not administered A. alternata
antigen or lavaged, but housed concurrently with the treated rats.
Lungs from all dose groups except the naïve group were lavaged
and infused with 10% neutral buffered formalin. Lungs from naïve
rats were only infused with 10% neutral buffered formalin. After
approximately 24 h, lung sections from all lobes were processed to
demonstrate maximum longitudinal sectioning of the right caudal
lobe and representative sections of the remaining right and left
lung lobes along with major bronchi and trachea. Sections were
processed and embedded in parafﬁn. Embedded tissues were cut
into 4–6 μm sections and stained with hematoxylin and eosin
(H&E). A histologic evaluation was performed on stained tissue
sections from multiple lobes and all the rats. The histology score
for each rat was based on alveolar damage, including alveolar
leukocyte inﬁltration and edema, epithelial cell hypertrophy, along
with perivascular and peribroncheolar cufﬁng and an estimate of
the area involved with disease. Grading was based on a severity
score scale of 0–5: 0 (no observable pathology), 1 (minimal or very
slight), 2 (mild or slight), 3 (moderate), 4 (marked), or 5 (severe).
The evaluation also included scoring any pre-existing chronic
background inﬂammation present in the Brown Norway rat model
(Noritake et al., 2007) and noted here in all the rats, including the
naïve rats, which was separately graded to avoid inﬂuencing the
evaluation of damage due to the A. alternata antigen.
2.7. Statistical analysis
Statistical analysis was performed using Prism Software (Graph-
Pad Software, Inc., La Jolla, CA). All measures were analyzed via one-
way or two-way ANOVA, with post-hoc Bonferroni analyses per-
formed on measures that showed signiﬁcant (Po0.05) overall effect.
2.8. Drugs
Budesonide was purchased from Sigma Chemical Co. (St. Louis,
MO, USA). MK-7246 was synthesized at Merck Research Laboratories.
Budesonide was dissolved in physiological (0.9%) salineþ0.5% Tween
80 (for intratracheal dosing) or 0.5% methylcelluloseþ0.24% sodium
dodecyl sulfate (for oral dosing). MK-7246 was dissolved in 0.5%
methylcelluloseþ0.24% sodium dodecyl sulfate.
3. Results
3.1. A. alternata induces dose and time-dependent eosinophil inﬂux
in the lungs of brown Norway rats
We ﬁrst determined the cellular proﬁle of BAL ﬂuid in BN rats,
following a single intratracheal challenge of A. alternata. Time and
dose-dependent increases in the number of total cells were
observed in the BAL ﬂuid recovered from BN rats (n¼8 per group)
following the intratracheal challenge with A. alternata (Fig. 1A).
There was a dose-dependent increase in the number of eosinophils
in the A. alternata treated rats, with maximal numbers at 48 h with
4921037108 cells ml1 compared to 2110374 cells ml1 in
the phosphate buffered saline (PBS) treated group (Po0.05)
(Fig. 1B). A dose related increase in neutrophils levels was also
observed reaching a peak levels at 24 h and were 5 fold less than
the eosinophils, reaching a maximum of 80103720 cells ml1
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for the 1000 μg dose compared to 2510377 cells ml1 for the
PBS treated group (Fig. 1C). Furthermore, we evaluated a more
detailed temporal proﬁle of inﬂammatory cell inﬂux in the lungs of
BN rats up to 96 h post A. alternata challenge in order to determine
the optimal time-point for future experiments. As observed pre-
viously, the total cells (Fig. 2A) and eosinophils (Fig. 2B) in the lungs
continued to increase following an A. alternata challenge, peaking at
48–72 h and remaining elevated for up to 96 h. By contrast, the
neutrophils levels reached their maximum levels 24 h after an
A. alternata challenge and rapidly declined in numbers reaching
almost PBS control levels by 72 h (Fig. 2C).
3.2. Cytokine production in A. alternata induced lung inﬂammation
in brown Norway rats
Since the production and release of Th2 cytokines such as
Interleukin-5 (IL-5) and IL-13 contribute to eosinophil inﬂux and
mucus secretion in humans as well as animal models of asthma, we
evaluated the levels of these cytokines in BAL ﬂuid recovered from BN
rats (n¼8 per group) 24, 48, 72 and 96 h following a single
intratracheal instillation of A. alternata. The levels of critical Th2
cytokines, such as IL-5 and IL-13, were signiﬁcantly elevated in the
BAL ﬂuid 24 h, reaching levels of 19547658 pgml1 for IL-5 and
4107156 pg ml1 for IL-13 in comparison to the PBS control
2577 pgml1 and 2075 pgml1 (respectively) (Po0.05). Elevated
levels continued at 48 h following an A. alternata challenge, reaching
levels of 14357370 pgml1 for IL-5 and 8067232 pgml1 for IL-13,
in comparison to the PBS control 2679 pgml1 and 1476 pgml1
(respectively) (Po0.05). Both, IL-5 and IL-13 returned to baseline
levels at 96 h (Fig. 3). A. alternata induced allergic responses develop
within a short timeframe, without the need for prior sensitization or
multiple challenges, a variety of early and late response cytokines may
be involved in the initiation of the inﬂammatory cascade. Therefore,
we tested the levels of a panel of early response cytokines and allergic
inﬂammation-relevant cytokines and chemokines in the BAL ﬂuid of
BN rats 6, 24 and 48 h following an A. alternata challenge. Early
response cytokines, such as interleukin-6 (IL-6) and interleukin-1
β (IL-1β) were signiﬁcantly increased at 6 h following the challe-
nge (Table 1), while IL-5, IL-13, Macrophage Inﬂammatory Protein-1α
(MIP-1α), Regulated on Activation, Normal T Cell Expressed and Secr-
eted (RANTES), and monocyte chemotactic protein-1 (MCP-1) were
signiﬁcantly increased at later time points (Fig. 3, Table 1).
3.3. Histopathology in A. alternata induced lung inﬂammation in
Brown Norway rats
To determine A. alternata induced histopathological changes in
the lungs of BN rats, we evaluated the temporal proﬁle of lung
pathology following an A. alternata challenge (Fig. 4).
Evaluation of the lungs from rats (n¼6 per group) dosed with
A. alternata antigen demonstrated a pronounced and persistent
alveolar inﬂammatory cell response and an increase in the
perivascular and peribronchiolar inﬂammatory response (Fig. 4B
and D), as compared to PBS-dosed rats (Fig. 4A and C), at all the
time-points investigated. All lung lobes evaluated were also
compared against lungs from naïve rats, in order to account for
any background inﬂammatory changes. The lungs of rats chal-
lenged with PBS demonstrated very slight alveolar inﬂammatory
changes, consisting of inﬁltration of neutrophils and eosinophils,
primarily during the earliest time-points. This was resolved by
72 h post-dose, when the changes were considered comparable to
naïve rats, indicating reversal of the minimal changes.
By comparison, inﬂammation in the alveolar spaces of A. alternata
antigen-dosed rats was more severe, as compared to the PBS-dosed
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Fig. 1. Effect of intratracheal dosing of A. alternata on BAL ﬂuid cells in the Brown Norway rat. Figure displays the effect of A. alternata dose–response curve (500–2000 μg,
intratracheal) on total cell counts (Panel A), eosinophils (Panel B) and neutrophils (Panel C) 24 and 48 h following direct instillation to the lungs. Each bar represents the
Mean7S.E.M. (n¼8 per treatment group). *Po0.05 compared to control animals receiving intratracheal PBS treatment.
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rats at all time-points. A notable perivascular and peribronchiolar
inﬂammation preceded alveolar inﬂammation 6 h following an A.
alternata challenge. At 24 h and 48 h following an A. alternata
challenge, there was a notable increase in polymorphonuclear cells
(PMNC). These cells were mainly eosinophils within alveolar spaces
that are associated with edema and ﬁbrin in addition to the
prominent perivascular and peribronchiolar inﬂammatory responses.
By 48 h, the lung lobes of A. alternata challenged rats contained
coalescing areas of inﬂammation (Fig. 4B and D). By 72 h, the affected
alveolar spaces were lined with hypertrophied epithelium, with
signiﬁcantly widened septa by macrophages and ﬁbroblasts and
alveolar spaces ﬁlled by mononuclear cells, occasional multinu-
cleated cells and rare PMNC.
3.4. Micro-CT imaging as a tool to monitor A. alternata induced
edema in the lung
To further investigate the pathophysiology of an A. alternata
challenge, we conducted micro-CT scanning in BN rats (n¼6 per
group) at 0, 24, and 48 h post A. alternata challenges. The total
edema, plus vasculature (E&V) volume, increased from 369757 to
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Table 1
Temporal proﬁle of various cytokines concentration following a single i.t. instilla-
tion of A.alternata.
Time post A. alternata challenge (h)
Cytokine (pg ml1) 6 24 48
MIP1α 250744 261a732 651a795
RANTES 973 21a73 42a76
MCP-1 18457525 1022271947 46,741a715,667
IL-6 487a743 154711 198736
IL-1b 49a714 2374 2175
a Po0.05 compared to control animals receiving i.t. PBS treatment.
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56075 mm3 by the 24 h time-point for the vehicle treated PBS
challenged group (Fig. 5). By 48 h post-PBS instillation, the E&V
increased to 6427118 mm3. The vehicle treated A. alternata group
had a baseline of 394735 mm3, which increased to 16547149mm3
by 48 h and resulted in a 5 fold increase from the baseline to
21037208 mm3 at 48 h (Fig. 5). A statistically signiﬁcant (Po0.05)
increase in E&V was observed in A. alternata challenged groups
compared to PBS group at 24 h with further increase over a period
of 48 h. The slight increase in E&V of edema after the PBS challenge
is most likely due to the reabsorption of the instilled ﬂuid in the
lung. Taken together, these data demonstrates that a single dose
of A. alternata induces pulmonary edema, cellular inﬁltration in
the lungs and the production of asthma-relevant cytokines and
chemokines.
3.5. Effect of prophylactic and therapeutic corticosteroid treatment
on A. alternata induced lung inﬂammation in Brown Norway rats
To examine the prophylactic effect of corticosteroids on A. alternata
elicited pulmonary inﬂammatory responses, we examined the effect of
intratracheally administered Budesonide (0.01, 0.1 and 1mg kg1) in
A. alternata challenged BN rats (n¼8 per group). Intratracheally dosed
Budesonide led to a dose-dependent decrease in the number of
eosinophils, which was maximal at 1 mg kg1 dose with complete
inhibition, compared to vehicle treated group at 48 h following the
intratracheal challenge with A. alternata (Po0.05) (Fig. 6). Oral
budesonide was administered to BN rats 2 h prior to and 22 h post
the A. alternata challenge and used as a positive control. As expected,
orally administered budesonide signiﬁcantly reduced A. alternata
induced eosinophil inﬂux in the lungs of BN rats. Similarly, intratra-
cheally dosed mometasone produced a dose dependent attenuation in
the number of eosinophils in the BAL ﬂuid recovered from BN rats
48 h following the intratracheal challenge with A. alternata (not
shown). These results demonstrate that intratracheal and the systemic
administration
of corticosteroids can suppress A. alternata induced allergic lung
inﬂammation in BN rats.
Since prophylactically administered corticosteroids suppressed
A. alternata induced pulmonary inﬂammation, we sought to
investigate if equivalent therapeutic dosing (after an A. alternata
challenge) of corticosteroids could also exert a similar effect. In
Fig. 7, we show that orally dosed budesonide (3 mg kg1) at 2, 6 or
23 h post an intratracheal challenge with A. alternata decreased
the number of eosinophils and cytokines, such as IL-5 and IL-13
levels, in a time dependent manner 48 h after the A. alternata
challenge. Budesonide dosed 1 h prior to A. alternata challenge
was used as a positive control. Eosinophil numbers (Fig. 7A)
following A. alternata challenge were signiﬁcantly decreased in
the BAL ﬂuid at the earlier therapeutic budesonide dosing time-
points (2 and 6 h post-challenge) with 9872% and 7179% of
inhibition respectively. In comparison to the later (23 h post
challenge) therapeutic dosing time-point inhibition, which inhib-
ited only 31712% of eosinophils at the 48 h time point. (Po0.05)
(Fig. 7).
IL-5 and IL-13 cytokine levels (Fig. 7 B and C) following
A. alternata challenge were signiﬁcantly decreased in the BAL ﬂuid
at the earlier therapeutic budesonide dosing time-points (2 and
6 h post-challenge), with 9873% and 10372% for IL-5 and
10371% and 10571% for IL-13 of inhibition respectively. In
comparison to the later (23 h post-challenge), therapeutic dosing
time- point inhibition, which produced only 31712% of eosino-
phils inhibition at the 48 h time point. (Po0.05) (Fig. 7a). In
addition, therapeutic dosing produced 81710% and 9074% of IL-
5 and IL-13 cytokine levels inhibition at the 48 h time point.
(Po0.05) (Fig. 7 B and C).
3.6. Effect of a CRTH2 antagonist on A. alternata elicited pulmonary
inﬂammation
In addition to corticosteroids, we also investigated whether the
inhibition of a clinically-relevant mechanism of allergic lung
Fig. 4. Histo-pathological evaluation of BN rats lung tissue following intratracheal instillation of A. alternata. Sections of lungs from rats (n¼6 per treatment group) following
a single instillation of either PBS (Panels A and C) or A. alternata (Panels B and D), and euthanized after 48 h. At 48 h, there is multifocal polomorphonuclear inﬂammatory cell
inﬁltrationwithin alveolar spaces of rats treated with A. alternata shown at low (Panel B) and higher magniﬁcation (Panel D). Rats treated with PBS demonstrated minimal to
no alveolar inﬂammatory cell inﬁltrates by 48 h as shown at low magniﬁcation (Panel A) and higher magniﬁcation inset (Panel C).
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inﬂammation such as CRTH2 would lead to a suppression of
inﬂammatory responses in A. alternata challenged Brown Norway
rats (n¼8 per group). Mast cell derived production of Prostaglan-
din D2 (PGD2) is believed to be a prime mediator of allergic
inﬂammation. Indeed, PGD2 is known to drive Th2 inﬂammation
through its receptor, CRTH2, which is expressed on Th2 cells,
eosinophils, basophils and innate lymphoid cells type 2 (ILC2).
Activation of CRTH2 has been shown to activate these cellular
subtypes and drive chemotaxis, as well as cytokine production,
including IL-4, IL-5 and IL-13. Since CRTH2 plays an important role
in the early aspects of the allergic inﬂammation cascade (Kostenis
and Ulven, 2006), we examined the effect of the CRTH2 antagonist
on A. alternata elicited pulmonary inﬂammatory responses. We
orally administered the CRTH2 inhibitor MK-7246, 1 h before and
23 h post-intratracheal instillation of the A. alternata. The MK-
7246 produced a dose dependent decrease in the number of
eosinophils with a maximal inhibition of 7475% in the
100 mg kg1 group (Po0.05) (Fig. 8 a), IL-5 (80712%) and IL-13
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Fig. 5. CT images of the lungs from Brown Norway rats 24 and 48 h following intratracheal instillation of A. alternata (n¼6 per treatment group). Upper panel (A) is
displaying representative images from PBS treated animals serving as a negative control group. In the lower panel (A) images are representative of animal lungs challenged
with A. alternata. Baseline measurements were taken 24 h prior to PBS or A. alternata instillation. A summary plot of the effects of PBS or A. alternata where each point
represents the Mean7S.E.M. (n¼6 per treatment group) is shown in panel (B). *Po0.05 compared to control animals receiving intratracheal PBS treatment.
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(76714%) cytokines levels (Po0.05) (Fig. 8 B and C). The results
reported show BAL ﬂuid recovered from BN rats 48 h following the
intratracheal. challenge with A. alternata. Orally dosed budesonide
was used as a positive control producing signiﬁcant inhibition of
eosinophilic inﬁltration as well as both IL-5 and IL-13 cytokine
levels. These results demonstrate that A. alternata induced eosi-
nophil inﬂux and inﬂammatory lung responses in BN rats may
serve as a valuable pharmacodynamic (PD) model to interrogate
pharmacological inhibition of asthma-relevant mechanisms.
4. Discussion
Asthma continues to be a signiﬁcant health concern (Polosa
and Benfatto, 2009). New emerging treatments, including ther-
apeutic antibodies to inﬂammatory cytokines (i.e. IL-5, IL-13, IL-4
and IL-17), allergen-speciﬁc immunotherapy, combination-inhaled
agents (i.e. ICS plus LAMA and or LABA), or small molecule
G-protein coupled receptors (i.e. CRTH2 antagonist), may ulti-
mately enhance the armaments used to treat this heterogeneous
disease. However, the effectiveness of these approaches is cur-
rently being determined in human asthma trials (Albertson et al.,
2013). From a preclinical perspective, animal models have been
historically useful in the progression of novel targets from the
laboratory to the clinic although their human predictability
remains subject of continuous debate (Canning, 2003). While
mouse models of allergic airway diseases have proven to be
invaluable for informing on various aspects and pathways related
to respiratory biology and pathology, they are not necessarily the
preferred species from a drug development perspective. The rat
has historically been the rodent species of choice for the majority
of nonclinical safety assessment and toxicology studies. There is a
signiﬁcant knowledge and many years of accumulated data
regarding baseline clinical chemistry and hematology ranges, as
well as database of compounds that have been evaluated in single-
and repeat-dose rat toxicology studies. In addition, a recent report
by Seok et al. (2013) suggested that genomic responses in mice
Fig. 6. Dose dependent effects of Budesonide in Brown Norway rats challenged
with A. alternata. Figure displays BAL ﬂuid eosinophils inﬂux 48 h after instillation
of a single dose of A. alternata. Each bar represents the Mean7S.E.M. (n¼8 per
treatment group). *Po0.05 compared to control A. alternata challenged animals
receiving intratracheal vehicle treatment (0.9% PBSþ0.5% Tween 80).
Fig. 7. Effect of a prophylactic or therapeutic Budesonide dosing in A. alternata challenged Brown Norway rats. Panel (A) illustrates the temporal proﬁle of eosinophils inﬂux
in the lung. Panels (B) and (C) illustrate IL-5 and IL-13 concentrations in the BAL ﬂuid after instillation of a single dose of A. alternata. Each bar represents the Mean7S.E.M.
(n¼8 per treatment group). *Po0.05 compared to control A. alternata challenged animals receiving p.o. vehicle treatment (0.5% MCþ0.24% SDS).
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poorly mimic human inﬂammatory diseases, thereby casting an
additional shadow on the translatability of mouse models to
human inﬂammatory diseases.
In humans, mounting evidence suggests that atopy to mold
allergens is related to asthma severity (Black et al. 2000; Zureik
et al., 2002; Denning et al., 2006). Here, we describe the respira-
tory impact of a single intratracheal instillation of A. alternata in
BN rats, with a goal of establishing a simple but clinically relevant
rodent asthma mechanism model that may be used to probe
pathway biology of novel pharmacological targets. The mucosal
surface of airway epithelium is the ﬁrst anatomical interface
where environmental allergens evoke host defense mechanisms.
Extracts from A. alternata spores have been shown to stimulate the
release of various pro-inﬂammatory cytokines including Thymic
stromal lymphopoietin (TSLP), granulocyte macrophage colony-
stimulating factor, and IL-33 from epithelial cells (Kouzaki et al.,
2009, Kouzaki et al., 2011). These events have been reported to be
dependent on Protease Activated Receptor-2 signaling and the
ST2 receptor (Boitano et al., 2011). Chronic instillation of the
A. alternata extract via the intranasal route in mice has been
shown to release IL-33, IL-5 and IL-13, followed by recruitment of
eosinophils in the BAL ﬂuid, independent of T or B cells involve-
ment (Doherty et al., 2012). These events have been described to
be mediated by innate lymphoid cells (ILC) (Bartemes et al., 2012),
which are capable of mediating asthma-like pathological environ-
ments, by secreting Th2 cytokines such as IL-5 and IL-13, prior to
the initiation of adaptive immune responses. The ILCs are not only
present in lungs, but in other organs such as intestines and have
been shown to produce Th2 cytokine in response to Interleukin-25
(IL-25) and IL-33 (Moro et al., 2010, Neill et al., 2010, Saenz, et al.,
2010). Although the repertoire of cytokines released by these ILCs
in different organs can vary, it appears that the common feature of
these cells is to mediate Th2 type allergic inﬂammatory responses
independent of adaptive immunity (Monticelli et al., 2012).
In our study, we found that a single intratracheal administra-
tion of A. alternata extract can mediate allergic responses similar
to some aspects of the human asthma phenotype. We established
a temporal proﬁle of differential cell recruitment and pro-
inﬂammatory cytokines after a challenge with an A. alternata
extract. The A. alternata challenge is characterized by the release
of early response pro-inﬂammatory cytokines such as IL-6, IL-1b,
MIP-1a and MCP-1. The A. alternata instillation triggers a small and
transient neutrophilic response which is resolved and returns to
baseline within 24 h. This is followed by a release of IL-5 and IL-13,
as detected in BAL ﬂuid. Both cytokines reached their peak around
48 h post-challenge and returned to basal levels within 72 h. In
addition to inﬂammatory responses, intratracheal instillation of
A. alternata leads to pathological changes, such as increased
alveolar inﬁltrates of neutrophils and eosinophils associated with
edema, as compared to rats dosed with PBS alone. The initial
perivascular and peribronchiolar inﬂammation was followed by
alveolar inﬂammation and cell accumulation, progressing to a
more sub-acute inﬂammatory response with notable epithelial
cell hypertrophy in affected areas at 72 h following an A. alternata
challenge. The cellular inﬁltration upon an A. alternata challenge
was further conﬁrmed in our CT imaging experiments measu-
ring the temporal proﬁle of microvascular leakage, leading to
lung edema.
In this study we also report the effect of commonly used
corticosteroids, such as budesonide on A. alternata challenged
Brown Norway rats. Budesonide dosed via an intratracheal and
oral route, 2 h prior to an A. alternata challenge, inhibited Th2
Fig. 8. Effects of CRTh2 antagonist MK-7246 in A. alternata challenged Brown Norway rats. Panel (A) shows effect on BAL ﬂuid eosinophils levels following MK-7246
administration. Panels (B) and (C) show IL-5 and IL-13 concentrations in the BAL ﬂuid following the MK-7246 treatment. Each bar represents the Mean7S.E.M. (n¼8 per
treatment group). *Po0.05 compared to control A. alternata challenged animals receiving p.o. vehicle treatment (0.5% MCþ0.24% SDS).
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cytokines and eosinophilia recruitment in the BAL ﬂuid in a dose
dependent manner. Interestingly, the maximal dose of budesonide
is partially effective if dosed 6 h after the challenge and completely
ineffective if dosed 23 h post an A. alternata challenge. Thus, our
results suggest that prophylactic budesonide intervention and the
blockade of early events mediated by A. alternata is an essen-
tial driver/event in this model. Pharmacological intervention of
corticosteroids is likely to occur at multiple stages during the
A. alternata elicited signaling pathways. Speciﬁcally, corticoster-
oids can either directly or indirectly regulate the transcription
(trans-repression) of various cytokines (i.e. IL-1, IL-2, IL-3, IL-4, IL-
5, IL-6, IL-9, IL-11, IL-12, IL-13, IL-18, TNFα), chemokines (i.e. IL-8,
RANTES, MIP-1α, MCP-1, eotaxin), adhesion molecules (vascular
cell adhesion moleculeintracellular cell adhesion molecule 1),
inﬂammatory enzymes, receptors and peptides (Barnes, 2006).
Therefore, our results show that budesonide profoundly impacted
IL-13 and IL-5 in the A. alternata model, which is consistent with
the already described pharmacology of corticosteroids (Braun
et al., 1997). In addition to evaluating the actions of corticosteroids
in our A. alternatamodel, we also proﬁled the impact of the CRTH2
antagonist, MK-7246. The antagonism of CRTH2, while not being
as efﬁcacious as the corticosteroid, budesonide, in response to an
A. alternata challenge, clearly impacted the eosinophil inﬂux, as
well as impacting overall IL-5 and IL-13 levels at 48 h. This is a
novel ﬁnding, in that CRTH2 is believed to be involved in an
adaptive immune response (Kostenis and Ulven, 2006), with
signiﬁcant effects in typical sensitized allergic models (Mauser
et al., 2013).
Recent investigations have expanded a role for CRTH2 outside
the initial adaptive immune response and have identiﬁed and
characterized CRTH2 on innate lymphoid cells as well (Mjösberg
et al., 2011). In response to an allergen, epithelial derived cytokines
(IL-25/IL-33/TSLP) promote a Th2 like response, by stimulating an
innate lymphoid population, which in turn can produce the
canonical IL-5 and IL-13 response (Licona- Limón et al., 2013).
The type 2 innate lymphoid cells (ILC2) represent a critical nexus
for expanding a Th2 repertoire in response to an epithelial insult
by parasites or allergens (Neill et al., 2010). Human ILC2s expres-
sing CRTH2 are responsive to both IL-25 and IL-33, resulting in
production of IL-13 (Mjösberg et al., 2012). Additional studies
directly demonstrated CRTH2 mediated induction of ILC2s migra-
tion and IL-4/IL-5/IL-13 production (Xue et al., 2013). In addition,
Xue et al., 2013, reported that CRTH2 up-regulated the expression
of receptor subunits for IL-33 and IL-25 (ST2 and Interleukin-17
Receptor A) in ILC2s. Furthermore, peripheral ILC2s demonstrated
a synergistic production of IL-13 that required CRTH2 stimulation,
along with the presence of IL-33 and IL-25 (Barnig et al., 2013).
CRTH2 expression on both innate, as well as adaptive lymphoid
cells, suggests an important role in modulating and controlling
Th2 inﬂammation. Currently, CRTH2 antagonism is being investi-
gated in clinical trials by several pharmaceutical companies for the
treatment of allergic diseases such as asthma, allergic rhinitis and
atopic dermatitis (Norman, 2014).
5. Summary
In summary, since no single animal model exhibits all facets of
asthma, animal models replicating various features of asthma are
important tools in investigating the mechanisms of the disease
pathogenesis and can provide an insight in identifying novel ther-
apeutic targets. Modeling asthma has proven to be challenging, in
part due to the clinical and pathophysiological complexity and
heterogeneity of the human disease. In this study we established a
novel pharmacodynamic model that recapitulates some cardinal
features of asthma pathogenesis and can be used as a tool in drug
discovery. Moreover, we demonstrated for the ﬁrst time that the
CRTH2 antagonist can reduce eosinophilia, most likely through
inhibiting ILC2 mediated responses in the A. alternatamodel. Further
studies are underway to establish the role of early cytokines releases,
leading to heighten eosinophilic responses and underlying pathology
after an A. alternata challenge.
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